EVERSANA Launches ORCHESTRATE PV: A Revolutionary AI Solution in Pharmacovigilance

EVERSANA Unveils ORCHESTRATE PV: A Leap into the Future of Pharmacovigilance

In a groundbreaking move for the pharmaceutical industry, EVERSANA recently announced the launch of its innovative platform, EVERSANA ORCHESTRATE PV. This advanced solution, powered by artificial intelligence, is set to transform pharmacovigilance processes, offering industry leaders a potent tool to manage drug safety operations more efficiently.

The Need for Transformation in Pharmacovigilance

The pharmacovigilance sector faces increasing challenges, with the need for speed, accuracy, and compliance becoming paramount. As pharmaceutical companies strive to ensure patient safety, the demand for effective drug monitoring and reporting systems has never been higher. In response to these challenges, EVERSANA has developed ORCHESTRATE PV, an AI-propelled platform aimed at streamlining these complex workflows.

Key Features of ORCHESTRATE PV

1. Accelerated Workflows: According to EVERSANA, ORCHESTRATE PV can enhance critical pharmacovigilance activities, including literature monitoring and reporting, up to five times faster than industry norms. With a staggering accuracy rate of 99.8%, this platform ensures that safety processes are not only quick but also reliable.

2. Seamless Integration: This user-friendly platform integrates effortlessly with widely used drug safety literature databases such as Oracle Argus Cloud, PubMed, and Embase. This integration facilitates a consolidated view of safety measures, enhancing the efficiency of data management.

3. Automation of Reporting Activities: The platform supports automated reporting features critical for compliance, such as the Periodic Adverse Drug Experience Report (PADER). This automation reduces the time spent on report generation by an average of 30 minutes per report compared to traditional manual processes.

4. Minimized Human Error: By leveraging AI technology, ORCHESTRATE PV dramatically decreases human errors by 90%, thus ensuring higher accuracy in reporting and data handling – a crucial aspect in the pharmaceuticals sector where precision is vital.

5. Scalability: One of the most notable aspects of ORCHESTRATE PV is its capacity for customization and scalability. The platform adapts to various operational demands, allowing organizations to adjust their workflows based on specific needs and market conditions.

Expert Insights

Jim Lang, CEO of EVERSANA, emphasized the company's commitment to making pharmacovigilance smarter and more efficient. He stated, "We remain as committed as ever to 'pharmatize AI.' Today, we bring pharmacovigilance leaders the long-overdue intelligent, scalable solution ... helping influence better patient outcomes." This perspective underscores the significance of innovation in enhancing patient safety and care.

In collaboration with Quantiphi, an AI-first digital engineering company, EVERSANA harnesses a blend of industry expertise and cutting-edge technology to address ongoing concerns within the life sciences sector. Asif Hasan, Co-founder of Quantiphi, remarked, "Together with EVERSANA, we are applying the full potential of AI to some of the most critical challenges in life sciences."

The Future of Pharmacovigilance

The introduction of ORCHESTRATE PV marks a significant step toward revolutionizing pharmacovigilance by integrating AI into everyday processes. In a landscape where regulatory compliance and patient safety are at the forefront, such technological advancements are crucial. As the industry moves forward, solutions like these will not only streamline operations but will also foster sustainable value across the pharmaceutical landscape.

For those interested in exploring this solution further or scheduling a demo, additional information is available on the EVERSANA website.

About EVERSANA

EVERSANA is a premier provider of global services tailored to the life sciences industry. With a focus on enhancing the patient experience, their solutions span all product life cycle stages, delivering consistent, long-term value for patients and healthcare providers alike. To learn more about EVERSANA's services and innovations, visit eversana.com.

Conclusion

The pharmaceutical industry stands at the cusp of a technological revolution, and EVERSANA's ORCHESTRATE PV is leading the charge towards more streamlined, accurate, and efficient drug safety processes. As AI continues to redefine the operational landscape, it promises to pave the way for a safer future in pharmaceuticals.